Imagen

Imagen Therapeutics specialises in developing clinically relevant 2/3D primary cell models for both cancer patients and the BioPharma industry.  Through accurate phenotypic drug sensitivity testing, oncologists are able to personalise treatment strategies for patients, and BioPharma are able to select cell models of their choice for pre-clinical and translational research.  Imagen have aspirations to build the world’s leading low passage, clinically relevant, living primary cell model BioBank, with matched patient blood samples, full clinical annotation and NGS.